The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1275-1281 , December 2005

Efficacy and safety of mometasone furoate nasal spray in nasal polyposis

  • Catherine Butkus Small, MD

      Affiliations

    • From Division of Infectious Diseases, New York Medical College
    • Corresponding Author InformationReprint requests: Catherine Butkus Small, MD, Division of Infectious Diseases, Munger Pavilion Rm. 245, Valhalla, NY 10595.
    • ,
  • Jaime Hernandez, MD

      Affiliations

    • Medellin Clinic
    • ,
  • Antonio Reyes, MD

      Affiliations

    • Otorrinolaringologo, Centro Médico Imbanaco, Cali
    • ,
  • Eric Schenkel, MD

      Affiliations

    • Drexel University School of Medicine, Philadelphia
    • ,
  • Angela Damiano, MD

      Affiliations

    • Division of Otolaryngology, New York Medical College
    • ,
  • Paul Stryszak, PhD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth
    • ,
  • Heribert Staudinger, MD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth
    • ,
  • Melvyn Danzig, PhD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth

Received 1 April 2005 ,Revised 28 June 2005 ,Accepted 5 July 2005.

References 

  1. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717–722
  2. Bachert C, Hormann K, Mosges R, Rasp G, Riechelmann H, Muller R, et al. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy. 2003;58:176–191
  3. Delank KW, Stoll W. [Sense of smell before and after endonasal surgery in chronic sinusitis with polyps]. HNO. 1994;42:619–623
  4. Bachert C, van Zele T, Gevaert P, De Schrijver L, Van Cauwenberge P. Superantigens and nasal polyps. Curr Allergy Asthma Rep. 2003;3:523–531
  5. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997;158:3902–3908
  6. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997;99:837–842
  7. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2:449–456
  8. Ebisawa M, Liu MC, Yamada T, Kato M, Lichtenstein LM, Bochner BS, et al. Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil-active cytokines. J Immunol. 1994;152:4590–4596
  9. Mygind N, Lildholdt T. Medical management. In:  Settipane GA,  Lund V editor. Nasal polyps: epidemiology, pathogenesis and treatment. Providence (RI): Oceanside Publications Inc; 1997;p. 147–155
  10. Badia L, Lund V. Topical corticosteroids in nasal polyposis. Drugs. 2001;61:573–578
  11. Ruhno J, Andersson B, Denburg J, Anderson M, Hitch D, Lapp P, et al. A double-blind comparison of intranasal budesonide with placebo for nasal polyposis. J Allergy Clin Immunol. 1990;86:946–953
  12. Vendelo Johansen L, Illum P, Kristensen S, Winther L, Vang Petersen S, Synnerstad B. The effect of budesonide (Rhinocort) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol Allied Sci. 1993;18:524–527
  13. Holmberg K, Juliusson S, Balder B, Smith DL, Richards DH, Karlsson G. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol. 1997;78:270–276
  14. Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg. 1998;124:513–518
  15. Tos M, Svendstrup F, Arndal H, Orntoft S, Jakobsen J, Borum P, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol. 1998;12:183–189
  16. Jankowski R, Schrewelius C, Bonfils P, Saban Y, Gilain L, Prades JM, et al. Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps. Arch Otolaryngol Head Neck Surg. 2001;127:447–452
  17. Filiaci F, Passali D, Puxeddu R, Schrewelius C. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Rhinology. 2000;38:185–190
  18. Lund VJ, MacKay IS. Outcome assessment of endoscopic sinus surgery. J R Soc Med. 1994;87:70–72
  19. Blomqvist EH, Lundblad L, Anggard A, Haraldsson PO, Stjarne P. A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. J Allergy Clin Immunol. 2001;107:224–228
  20. Berkowitz RB, Roberson S, Zora J, Capano D, Chen R, Lutz C, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 1999;20:167–172
  21. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther. 1997;19:27–38discussion 2-3
  22. Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98:724–731
  23. Rowe-Jones JM, Mackay IS. Management of nasal polyps. Curr Opin Otolaryngol Head Neck Surg. 1998;6:41–46
  24. Johansson L, Bramerson A, Holmberg K, Melen I, Akerlund A, Bende M. Clinical relevance of nasal polyps in individuals recruited from a general population-based study. Acta Otolaryngol. 2004;124:77–81
  25. Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin Pharmacother. 2003;4:1579–1591
  26. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol. 2000;106(suppl 4):S179–S190

 Supported by a grant from the Schering-Plough Research Institute.Disclosure of potential conflict of interest: Dr Small received research support from PO 1998 SAR Study, PO 1925 Polyp Study, PO 2573 Follow-Up to Polyp Study, PO 2683 Acute Rhinosinusitis, and PO 2692 Acute Rhinosinusitis. Dr Stryszak, Dr Staudinger, and Dr Danzig are employed by Schering-Plough. Dr Schenkel has consultant arrangements with Schering-Plough and Sanofi-Aventis; receives research support from Schering-Plough, Sanofi-Aventis, and Glaxo; and is on the speakers bureau for Schering-Plough, Sanofi-Aventis, and Glaxo. All other authors have no conflict of interest to disclose.

PII: S0091-6749(05)01712-4

doi: 10.1016/j.jaci.2005.07.027

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1275-1281 , December 2005

Article Tools

* Image Usage & Resolution